1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

New Report Calls For Pushing And Pulling In Global Fight Against Superbugs

 
• By Joseph Haas

New DRIVE-AB report on revitalizing antibiotic R&D suggests market-entry rewards of up to $1bn for companies introducing novel products, cites need for increasing public funding of R&D support.

Antibiotic resistant bacteria closeup biofilm

A new international report on encouraging R&D for novel antibiotics says that while governments are contributing an estimated $550m annually toward these efforts, an even higher amount of funding is needed. DRIVE-AB's Revitalizing The Antibiotic Pipeline report recommends both "push" incentives like R&D funding and "pull" incentives such as market-entry rewards to companies that bring novel antibiotics to market as ways to address the rising global issue of drug-resistant microbial infections.

Overall, the report – developed over three years by a task force commissioned by the EU's Innovative Medicines Initiative – proposes a set of measures it says would cost $36bn...

DRIVE-AB at a glance
  • A project of the Innovative Medicines Initiative's NewDrugs4BadBugs effort
  • Name stands for: Re-investment In R&D And Responsible Antibiotic Use
  • Task force comprised of public- and private-sector representatives...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Therapy Areas

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.